Visit Flagship at the Spatial Biology for Drug Development Summit. October 11-13, 2023. Join us at the inaugural Spatial Biology for Drug Development Summit to explore implementation strategies, challenges in interpretation, and how this rapidly changing technology is...
Visit us at booth E30 to learn how we can partner for end-to-end support of your research and development program. We help you analyze more data in more depth, so you can produce more effective therapies. Attending the 13th Annual World Clinical Biomarkers & CDx...
Flagship Bioscience is your source for spatial biology expertise, moving your research forward every step of the way. Our mission is to explore complex biomarkers within the context of disease in order to advance your precision medicine strategy. Attending the 2023...
Visit us at booth 821 at the ASGCT Annual Meeting. We help you analyze more data in more depth, so you can produce more effective therapies. Attending the ASGCT Annual Meeting? Schedule a meeting with our team to discuss our: AI-powered digital pathology solutions...
Visit Us at Booth 2866 in the West Building, Level 2 Flagship Biosciences is your source for spatial biology expertise, moving your research forward every step of the way. Our mission is to explore complex biomarkers within the context of disease in order to advance...
Reuniting 100+ leading experts in biotech, pharma, and academia. February 21-23, 2023. We’re headed to Boston to join other leading experts in biotech, pharma and academia to discuss obstacles in clinical trials and strategies for delivering safer and more effective...
Sign up to receive industry and company news, including The Cut Point, Flagship’s quarterly e-newsletter.
NEWS
Accomplished industry executive strengthens company’s position as a leader in spatial biology and biomarker analytics.BROOMFIELD, CO - September 27, 2022 — Flagship Biosciences, Inc., a leader in spatial biology and biomarker analytics services, announced the hiring...
Acquisition significantly expands Flagship’s portfolio of biomarker and analytics servicesBroomfield, CO – August 31, 2022 — Flagship Biosciences, Inc., a leader in spatial biology and biomarker analytics services, announced the acquisition of Interpace Pharma...
The journal Scientific Reports recently published a manuscript on the validation of Flagship’s new digital assay, Tissue Insight (TI) 22C3 NSCLC.1 This technology facilitates the otherwise cumbersome process of quantifying programmed cell death ligand 1 (PD-L1)...
PUBLICATIONS/POSTERS
Background Historically, immunohistochemistry (IHC) assays have been designed for simplicity of manual pathology, however, this is not always ideal to acquire the appropriate data for patient selection and outcomes. Due to various challenges within the current...
In the downloadable original research article sponsored by Pfizer, the digital tissue analysis was performed using the Flagship Biosciences proprietary Image Analysis platform. The article was published in the Journal: Clinical Cancer Research online first on June 3,...
In partnership with Leap Therapeutics (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, Flagship Biosciences published this downloadable original research article. It was first published on Monday, May 10...